Navigation Links
EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
Date:4/22/2008

ROCKVILLE, Md., April 22 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that the Company's Board of Directors has decided against seeking stockholder approval for a reverse stock split at the Annual Meeting of Stockholders to be held on June 5, 2008. In light of recent gains in the Company's stock price, management's confidence in the Company's product candidate pipeline and the Company's current cash position, the Board of Directors concluded that it is not necessary to seek stockholder approval of a reverse stock split at this time.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

On April 4, 2008, the Company issued a press release disclosing that it had received a Deficiency Notice from the Listing Qualifications Department of the NASDAQ Stock Market, LLC, and had announced its intention to seek stockholder approval for a reverse stock split. The Company remains committed to becoming compliant with all Nasdaq listing requirements.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation.

MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. ENMD-1198, a novel antimitotic agent, and ENMD-2076, a selective kinase inhibitor, are in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is t
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
2. EntreMed Receives Nasdaq Deficiency Notice
3. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
4. EntreMed Announces 2008 Corporate and Clinical Program Priorities
5. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
6. EntreMed to Present at BIO CEO and Investor Conference
7. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
8. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
9. EntreMed Appoints Senior Vice President of Research and Development
10. EntreMed to Present at ThinkEquity Partners 5th Annual Growth Conference
11. Glass Lewis & Co. Recommends Renovis Shareholders Vote For Merger With Evotec

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...RNewswire/--BlueMarbleEnergyCorp.announcedtodaytha...OPDA)wererecentlyawarded$2millionbyWashingtonState...vate/publicpartnershiptoconstructthestate,sfirstsp..., "Thisinvestmentwillsignificantlyspeedthedevel...colnCounty,"saidBlueMarbleEnergyCEOKellyOgilvie."W...
(Date:11/24/2009)...,, TORONTO,Nov.24/PRNewswire-FirstCall/-Hamilto...aleadingproviderofadvancedlasersystemsandinstrumen...todayreportedoperationalandfinancialresultsforthet...ghts,-Revenuewas$1.46millioncomparedwith$1.43mill...edwith66.1percentinQ3,2008,-Netlossreducedto$148,0...
(Date:11/24/2009)...f.,Nov.24/PRNewswire-FirstCall/--GenomicHealth,Inc...icHealth,sExecutiveChairman,willpresentatthe21stAn...nTuesday,December1,2009at10:00a.m.ET. ,, Toacce...tation,visittheInvestorRelationssectionofGenomicHe....Pleaseconnecttothewebsiteatleast15minutespriortot...
(Date:11/24/2009)... Chemical Abstracts Service (CAS), the global exp...patent office is now the world,s leading producer ...na trailed Japan,s patent office, the World Intell...d States Patent and Trademark Office (USPTO) for m...IPO in 2006, and exceeded Japan for the first time...
Breaking Biology Technology:Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2Hamilton Thorne announces third quarter results 2Hamilton Thorne announces third quarter results 3Hamilton Thorne announces third quarter results 4Hamilton Thorne announces third quarter results 5Hamilton Thorne announces third quarter results 6Hamilton Thorne announces third quarter results 7Genomic Health to Present at Piper Jaffray Health Care Conference 2China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information 2China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information 3
...ows by nearly 90%, operating loss reduced by 73% ,... (Nasdaq: VSCP ), a leading provider of quantita...that revenues for the fourth quarter of 2008 were ...s fourth quarter. Revenues for the year ended Dece...ared to $5.6 million in the comparable period in 2...
...ia, February 25 BN,ImmunoTherapeutics, Inc. annou...C(TM) since the vaccine was licensed from the Nati...The data, that once again confirms the,excellent s...ll be presented,at the 2009 Genitourinary Cancers ... Florida. , Abstracts from three different stu...
...r Oils drive better restaurant menu options , , I...th marks a significant milestone in North America ... of trans and saturated fats over the past three y...-9 Canola and Sunflower Oils, developed by Dow Agr...nds of trans fat, and 130 million pounds of satura...
Other Biology Technology:VirtualScopics Achieves Operating Cash Flow Breakeven in the Fourth Quarter 2008; Reports Record 2008 Revenue and Gross Profit 2VirtualScopics Achieves Operating Cash Flow Breakeven in the Fourth Quarter 2008; Reports Record 2008 Revenue and Gross Profit 3VirtualScopics Achieves Operating Cash Flow Breakeven in the Fourth Quarter 2008; Reports Record 2008 Revenue and Gross Profit 4VirtualScopics Achieves Operating Cash Flow Breakeven in the Fourth Quarter 2008; Reports Record 2008 Revenue and Gross Profit 5VirtualScopics Achieves Operating Cash Flow Breakeven in the Fourth Quarter 2008; Reports Record 2008 Revenue and Gross Profit 6VirtualScopics Achieves Operating Cash Flow Breakeven in the Fourth Quarter 2008; Reports Record 2008 Revenue and Gross Profit 7BN ImmunoTherapeutics Reports Further Data on PROSTVAC(TM) 2BN ImmunoTherapeutics Reports Further Data on PROSTVAC(TM) 3Heart Health Month Milestone: Half a Billion Pounds of Bad Fats Eliminated From North American Diet 2Heart Health Month Milestone: Half a Billion Pounds of Bad Fats Eliminated From North American Diet 3
(Date:11/25/2009)...the Cell Death Research Laboratory in the Universi...ded the prestigious Johnson & Johnson Focused Fund...brain cell damage in Parkinson,s disease. The awar...port of innovation and excellence in science, was ...r this month at an event at the Hyatt Regency Hote...
(Date:11/24/2009)... been prescribed by traditional healers in Brazil ...omach pain to fever and flu. , Now for the first ...n able to scientifically prove the pain relieving ... Brazilian mint. , Testing this ancient South Ame...ciela Rocha was able to show that when prepared as...
(Date:11/24/2009)...remarkable class of ring-shaped protein motors has...erkeley National Laboratory (Berkeley Lab) using a... at the Advanced Light Source (ALS). These protein...replication, and are vital to the survival of all ...ch as the human papillomavirus, which has been lin...
Breaking Biology News(10 mins):Johnson & Johnson award goes to research of the cause of brain cell damage in Parkinson's 2Got a pain? -- Have a cup of Brazilian mint 2Atomic-level snapshot catches protein motor in action 2Atomic-level snapshot catches protein motor in action 3Atomic-level snapshot catches protein motor in action 4Skunks strategy not just black and white 10686 1Skunks strategy not just black and white 10686 2 26 23163 3B7 5 million 28 2412 6 million 29 collaborations lead UK research communitys response to H1N1 pandemic 10683 1 26 23163 3B7 5 million 28 2412 6 million 29 collaborations lead UK research communitys response to H1N1 pandemic 10683 2 26 23163 3B7 5 million 28 2412 6 million 29 collaborations lead UK research communitys response to H1N1 pandemic 10683 3 26 23163 3B7 5 million 28 2412 6 million 29 collaborations lead UK research communitys response to H1N1 pandemic 10683 4D A R E Partners with MedSafe to Tackle Teen Prescription and Over the Counter Drug Abuse at Home 61134 1D A R E Partners with MedSafe to Tackle Teen Prescription and Over the Counter Drug Abuse at Home 61134 2D A R E Partners with MedSafe to Tackle Teen Prescription and Over the Counter Drug Abuse at Home 61134 3
...earchers at the University of Pennsylvania School ...d by lung-infecting bacteria further shuts down a ...nts. The disruption to this protein that conveys i...to buildup inside the lung. The finding suggests a...ns in some cystic fibrosis (CF) patients. , Lung...
...anol is widely touted as an eco-friendly, clean-bu...tes ran on fuel made primarily from ethanol instea...ted deaths and hospitalizations would likely incre...ty atmospheric scientist Mark Z. Jacobson. His fin... of the journal Environmental Science & Techno...
... critical characteristics of breast cancer that ar...uring gene expression in the tumor, a research tea...D. Anderson Cancer Center reports in Lancet Oncolo... new genomic microarray test that identifies wheth...e estrogen and the role of a growth factor recepto...
Other Biology News:Penn study on lung-infecting bacterial enzyme suggests new approach to cystic fibrosis treatment 2Ethanol vehicles pose a significant risk to human health, study finds 2Ethanol vehicles pose a significant risk to human health, study finds 3Gene expression test reveals ER and HER-2 status of breast tumors 2
...96 x 0.2 ml reaction module is used for nucleic ac...d with an interchangeable 96-well reaction module ...h optical modules for real-time PCR and features t...ock, or in-sample probe. It includes the iCycler b...
... benchtop and stackable multi-function incubator. ...isplay screen to accurately control temperature an...y distribute temperature in the incubator. Tempera...sor controller. Built in maintenance-free stepping...
Rabbit Anti-Autotaxin / ENPP2 Antibody, Unconjugated from Cosmo Bio Co., Ltd.
Mouse Anti-Human TNPO2 Polyclonal Antibody, Unconjugated from Novus Biologicals
Biology Products: